Do compounding pharmacies need products liability insurance?

503A traditional compounding pharmacies operate under state board oversight with patient-specific prescriptions. The primary professional liability vehicle is druggist professional liability - covering pharmacist-as-professional exposure with limits typically $1M/$3M.

Products liability sits beneath druggist PL as a secondary layer at $1M-$2M typical. The exposure is tied to compounded preparations entering commerce - sterility failures, compounding errors, dispensing errors. PBM credentialers and patient-facing dispensing rarely demand higher than $1M/$2M for 503A operators.

GLP-1 compounding and sterile-injectable compounding may push limits higher - some specialty 503A operators carry $3M-$5M products. Post-2024 GLP-1 carrier exits have made even baseline 503A products coverage harder to place than previously.

503B outsourcing facilities operate under FDA registration with cGMP compliance, compounding office-stock product for hospitals rather than patient-specific prescriptions. The primary line flips: products liability becomes primary at $5M-$10M (driven by hospital purchase contract demands), with druggist PL as secondary.

Hospital purchase contracts almost universally require $5M-$10M products with hospital additional-insured (CG 20 10 + CG 20 37 on primary/non-contributory basis), waiver of subrogation, 30-day notice of cancellation, and FDA registration documentation. Credentialing platforms (Symplr, Reptrax, Vendormate) validate the COI line by line.

cGMP-aligned property forms with validation loss endorsement are also load-bearing for 503Bs - generic pharmacy property is materially inadequate for the validation cost exposure on a batch loss.

The most common 503A-to-503B insurance failure: a 503A pharmacy that registers as a 503B and renews its program on the existing 503A architecture. The result: a druggist-PL-centric program with $1M/$2M products and generic pharmacy property forms, walking into hospital purchase contracts that require $5M-$10M products, cGMP-aligned property, FDA-registration COIs, and named-additional-insured with primary/non-contributory wording.

The fix is rarely an endorsement; it is a ground-up rebuild against the new exposure base. Three program changes before the FDA registration goes effective: (1) rebuild products liability to $5M-$10M with cGMP-aware carriers, (2) replace generic pharmacy property with drug-manufacturer property forms covering validation losses, (3) add or right-size recall coverage with FDA-specific extension wording.

A Texas 503A in the $2M-$10M revenue range generally runs $8,000-$35,000 annually for the full program. A 503B at comparable revenue runs $75,000-$400,000+ depending on revenue, product mix (sterile injectables, GLP-1, oncology raise the floor significantly), and hospital purchase contract obligations.